United Therapeutics Corp. (UTHR) - 2025 Annual Report Summary
Business Context and Reporting Period
This summary covers the Form 10-K for United Therapeutics Corporation for the fiscal year ended December 31, 2025. United Therapeutics is a public benefit corporation focused on developing therapies for rare diseases, primarily pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), as well as high-risk neuroblastoma. The company is also heavily invested in organ manufacturing technologies, including xenotransplantation and regenerative medicine.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenues | $3,182.7 million | $2,877.4 million | +11% |
| Net Income | $1,334.7 million | $1,195.1 million | +12% |
| Diluted EPS | $27.86 | $24.64 | +13% |
| Operating Cash Flow | $1,561.2 million | $1,327.1 million | +18% |
| Cash & Investments | $4,697.0 million | $4,742.3 million | -1% |
| Debt Outstanding | $0 | $300.0 million | Repaid |
Revenue by Product (2025):
- Tyvaso (DPI + Nebulized): $1,878.2 million (59% of total revenue)
- Remodulin: $526.8 million (17% of total revenue)
- Orenitram: $496.9 million (16% of total revenue)
- Unituxin: $226.8 million (7% of total revenue)
- Adcirca: $30.0 million (1% of total revenue)
Material Changes vs. Prior Period
- Revenue Growth: Driven primarily by a 25% increase in Tyvaso DPI sales ($1,292.5M) and a 14% increase in Orenitram sales. Growth was attributed to increased patient utilization and the Medicare Part D benefit redesign under the Inflation Reduction Act (IRA).
- Competition: Liquidia launched Yutrepia (a competing dry powder treprostinil) in June 2025. Management states there has been no material impact on net revenues to date, but litigation regarding patent infringement is ongoing.
- Debt Reduction: The company terminated its 2022 Credit Agreement and entered a new $2.5 billion facility in April 2025. All borrowings were repaid by June 2025, leaving the company debt-free as of year-end.
- Share Repurchases: The company executed a $1.0 billion accelerated share repurchase program in 2025, repurchasing approximately 2.64 million shares.
- Legal Accruals: A $71.1 million litigation accrual was recorded in 2024 related to a breach of contract claim by Sandoz; an additional $3.0 million was accrued in 2025. The appeal is pending.
Guidance, Outlook, and Risks
Outlook: Management anticipates near-term revenue growth driven by Tyvaso DPI, Orenitram, and modest price increases. Medium-to-long-term growth is expected from new products (ralinepag), new indications (IPF/PPF for Nebulized Tyvaso), and organ manufacturing technologies.
Key Pipeline Updates:
- TETON 2 Study: Met primary endpoint for Nebulized Tyvaso in Idiopathic Pulmonary Fibrosis (IPF) in September 2025. TETON 1 data readout expected in Q1/Q2 2026.
- Ralinepag: Phase 3 ADVANCE OUTCOMES study enrollment concluded in June 2025; topline data expected Q1/Q2 2026.
- Xenotransplantation: The EXPAND study for the UKidney product began in Q4 2025. The EXTEND study IND for UThymoKidney was cleared in August 2025.
Material Risks:
- Competition: Launch of Yutrepia and potential generic entry for Nebulized Tyvaso (Watson) as early as January 2026 and Orenitram (Actavis/ANI) in 2027.
- Regulatory/Pricing: Impact of the Inflation Reduction Act (IRA) on Medicare Part D rebates and potential future pricing pressures from the Trump administration's "Most Favored Nation" proposals.
- Manufacturing: Reliance on single-source suppliers for key products (e.g., MannKind for Tyvaso DPI, DEKA for Remunity pumps) and limited backup capacity for Unituxin.
- Legal: Ongoing patent litigation with Liquidia and Sandoz, and appeals regarding charitable donation practices (MSP Recovery/Humana/United Healthcare).
Investor Verification Checklist
- Yutrepia Impact: Monitor future quarterly reports for any erosion in Tyvaso DPI market share following the June 2025 launch of Yutrepia.
- Generic Timelines: Verify the status of Watson's ANDA for Nebulized Tyvaso and the potential for earlier market entry than the agreed January 2026 date.
- IRA Rebate Impact: Assess the net effect of the new Medicare Part D manufacturer discounting program on Orenitram and Tyvaso DPI net prices versus volume growth.
- Legal Resolutions: Track the outcome of the Sandoz appeal and the Liquidia patent litigation, which could result in significant damages or label restrictions.
- Xenotransplantation Milestones: Monitor the safety and efficacy data from the EXPAND and EXTEND clinical trials, as these represent high-risk, high-reward long-term value drivers.